411 related articles for article (PubMed ID: 28111228)
1. Targeted Therapies for Ovarian Cancer.
Grunewald T; Ledermann JA
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():139-152. PubMed ID: 28111228
[TBL] [Abstract][Full Text] [Related]
2. From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer.
Gómez-Raposo C; Mendiola M; Barriuso J; Hardisson D; Redondo A
Expert Opin Investig Drugs; 2011 May; 20(5):591-4. PubMed ID: 21452927
[TBL] [Abstract][Full Text] [Related]
3. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
5. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
6. Targeted agents and combinations in ovarian cancer: where are we now?
McLachlan J; Lima JP; Dumas L; Banerjee S
Expert Rev Anticancer Ther; 2016; 16(4):441-54. PubMed ID: 26942837
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in the diagnosis and treatment of ovarian cancer.
Jelovac D; Armstrong DK
CA Cancer J Clin; 2011; 61(3):183-203. PubMed ID: 21521830
[TBL] [Abstract][Full Text] [Related]
8. [The molecular biology of epithelial ovarian cancer].
Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
10. New developments in molecular targeted therapy of ovarian cancer.
Guan LY; Lu Y
Discov Med; 2018 Nov; 26(144):219-229. PubMed ID: 30695681
[TBL] [Abstract][Full Text] [Related]
11. [New drugs and targeted therapeutic agents in ovarian cancer].
de La Motte Rouge T; Petrella MC; Michels J; Even C; Balleyguier C; Duclos J; Mazeron R; Morice P; Pautier P; Lhommé C
Bull Cancer; 2009 Dec; 96(12):1215-24. PubMed ID: 19919916
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy of ovarian cancer including immune check point inhibitor.
Kim JY; Cho CH; Song HS
Korean J Intern Med; 2017 Sep; 32(5):798-804. PubMed ID: 28823141
[TBL] [Abstract][Full Text] [Related]
13. [Individualized treatment for ovarian cancer may become possible].
Kjölhede P; Dahm-Kähler P; Tholander B; Åvall Lundqvist E
Lakartidningen; 2015 Dec; 112():. PubMed ID: 26646960
[TBL] [Abstract][Full Text] [Related]
14. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
15. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
16. Advances in ovarian cancer therapy.
Cortez AJ; Tudrej P; Kujawa KA; Lisowska KM
Cancer Chemother Pharmacol; 2018 Jan; 81(1):17-38. PubMed ID: 29249039
[TBL] [Abstract][Full Text] [Related]
17. [IV. Targeted therapies for epithelial ovarian cancer].
Mabuchi S; Sasano T; Kawano M; Kimura T
Gan To Kagaku Ryoho; 2014 Feb; 41(2):193-8. PubMed ID: 24826387
[No Abstract] [Full Text] [Related]
18. Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches.
Farolfi A; Gurioli G; Fugazzola P; Burgio SL; Casanova C; Ravaglia G; Altavilla A; Costantini M; Amadori A; Framarini M; Ansaloni L; De Giorgi U
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130614
[TBL] [Abstract][Full Text] [Related]
19. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC; Fleming GF; Lengyel E
Obstet Gynecol; 2021 Jan; 137(1):108-121. PubMed ID: 33278287
[TBL] [Abstract][Full Text] [Related]
20. Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.
Cornelison R; Llaneza DC; Landen CN
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29057791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
